| Program | Target(s) | Indication(s) | Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Commercial rights |
|---|---|---|---|---|---|---|---|---|
| Firi-cel* (CRG-022) | CD22 | R/R LBCL - post CD19 CAR T |  | |||||
| Firi-cel* (CRG-022) | CD22 | LBCL - CAR T naïve(1) | | |||||
| Firi-cel* (CRG-022) | CD22 | Pediatric B-ALL | | |||||
| CRG-023 (tri-specific CAR T with CD2 co-stimulation) | CD19 CD20 CD22 |
B-cell malignancies | | |||||
CARGO is developing multi-specific CAR T-cell therapies with CD2 co-stimulation designed to overcome multiple resistance mechanisms – antigen loss, co-stimulation (CD58) loss and lack of persistence. With a multi-targeted approach, it has the potential to treat several hematologic malignancy types.
Our most advanced preclinical program, CRG-023, incorporates a tri-specific CAR to address either tumor antigen loss (e.g., CD19) or low-density antigen expression, loss of costimulation (e.g., CD58) and lack of T-cell persistence. CRG-023 is designed to target tumor cells with three B-cell antigen targets, CD19, CD20 and CD22. This product candidate also integrates a CD2 costimulatory domain into the tri-specific CAR T-cell to counter a target-independent mechanism, the downregulation of COSS (the ligand of the CD2 costimulatory receptor), that leads to resistance to CAR T-cells and other immune therapies.
